Literature DB >> 2499481

Intravenous and subcutaneous administration of a long-acting somatostatin analogue: effects on glucose metabolism and splanchnic haemodynamics in healthy subjects.

L S Eriksson1, J Wahren.   

Abstract

The effect of SMS 201-995, a long-acting somatostatin analogue, on splanchnic blood flow and glucose metabolism, was investigated in five groups of healthy subjects. Groups A (n = 4), B (n = 5), C (n = 5) and D (n = 5) were studied before, during and after a 60-min intravenous infusion of SMS (1.7, 0.8, 0.2 and 0.1 micrograms min-1, respectively). Group E (n = 6) was investigated before and for 6 h after a subcutaneous injection of 25 micrograms of SMS. The splanchnic blood flow decreased by 20-25% in all groups in response to SMS and remained low during the entire observation periods. Arterial concentrations of glucose showed a 15-20% decline during SMS infusion in Groups A and B (P less than 0.05-0.01) and a less pronounced decrease in the other groups. Fifteen minutes after the end of infusion the glucose levels started to rise and in group A, the levels were significantly higher than basal (+25%, P less than 0.05-0.01) at 90-180 min after the end of infusion. The net splanchnic glucose production, determined in groups A and B, decreased by 65-75% in response to SMS infusion. Towards the end and immediately after the infusions, however, the net glucose output increased, but decreased again at 30-60 min after the end of infusion. Arterial, insulin and glucagon concentrations decreased significantly during infusion in all groups. This decline was more pronounced for insulin (50%) than for glucagon (20-25%) and insulin concentrations remained low for a longer period after the end of infusions.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2499481     DOI: 10.1111/j.1365-2362.1989.tb00220.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  7 in total

1.  The harm of prophylactic octreotide in pancreatoduodenectomy: more artefact than fact?

Authors:  Xihua Yang; Shirali Patel; Steven C Cunningham
Journal:  HPB (Oxford)       Date:  2015-01-27       Impact factor: 3.647

2.  Effects of octreotide on cardiovascular hormones and haemodynamics in conscious dogs.

Authors:  J Donckier; L Stoleru; P Selvais; L Galanti; H Van Mechelen; J M Ketelslegers; A A Charlier
Journal:  J Endocrinol Invest       Date:  1996-02       Impact factor: 4.256

3.  Prophylactic octreotide for pancreatoduodenectomy: more harm than good?

Authors:  Matthew T McMillan; John D Christein; Mark P Callery; Stephen W Behrman; Jeffrey A Drebin; Tara S Kent; Benjamin C Miller; Russell S Lewis; Charles M Vollmer
Journal:  HPB (Oxford)       Date:  2014-07-10       Impact factor: 3.647

4.  Effects of somatostatin (SMS) on pancreatic microcirculation.

Authors:  T Plusczyk; D Rathgeb; S Westermann; G Feifel
Journal:  Dig Dis Sci       Date:  1997-11       Impact factor: 3.199

5.  Effects of the long-acting somatostatin analogue octreotide on abomasal function and plasma level of insulin and glucagon in sheep.

Authors:  K Holtenius
Journal:  Acta Vet Scand       Date:  1994       Impact factor: 1.695

6.  The location of the human volume indifferent point predicts orthostatic tolerance.

Authors:  Sara S Jarvis; James A Pawelczyk
Journal:  Eur J Appl Physiol       Date:  2010-01-26       Impact factor: 3.078

7.  Refractive properties of the healthy human eye during acute hyperglycemia.

Authors:  Nanouk G M Wiemer; Elisabeth M W Eekhoff; Suat Simsek; Robert J Heine; Peter J Ringens; Bettine C P Polak; Michiel Dubbelman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-04       Impact factor: 3.117

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.